Related Experiment Videos
Lipoprotein(a) concentrations are increased in patients with myocardial infarction and angiographically normal
M S Graziani1, L Zanolla, G Righetti
1Laboratorio di Chimica Clinica ed Ematologia, Ospedale Civile Maggiore, Verona, Italy.
Insights
Lipoprotein(a) [Lp(a)] may impact cardiovascular disease by affecting the fibrinolytic system, not just lipid metabolism. Elevated Lp(a) levels were observed in myocardial infarction patients regardless of coronary artery disease severity, suggesting a role in blood clot formation.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Hematology
Background:
- Lipoprotein(a) [Lp(a)] is recognized as an independent risk factor for cardiovascular diseases.
- The precise mechanism of Lp(a)'s pathogenicity is debated, with potential roles in lipid metabolism or the fibrinolytic system.
- Lp(a)'s apolipoprotein component shares similarities with plasminogen, hinting at a connection to blood clot breakdown.
Purpose of the Study:
- To investigate the role of Lp(a) in cardiovascular disease by comparing patients with myocardial infarction (MI) and differing coronary artery disease (CAD) statuses.
- To differentiate whether Lp(a)'s pathological effects are primarily linked to lipid metabolism disturbances or the fibrinolytic system.
Main Methods:
- Comparison of two patient groups: those with MI and angiographically documented coronary artery disease (CAD), and those with MI but without obstructive CAD.
- Assessment of lipid metabolism profiles, thrombogenicity indices, and Lp(a) values in both groups.
- Analysis of Lp(a) concentrations, specifically focusing on levels above 300 mg/l.
Main Results:
- Significant differences in lipid metabolism were observed between the two MI groups.
- However, thrombogenicity indices and Lp(a) values were similar across both groups.
- A high frequency of Lp(a) concentrations exceeding 300 mg/l was found in MI patients, irrespective of the presence or absence of obstructive CAD.
Conclusions:
- The findings support the hypothesis that Lp(a) plays a role in the fibrinolytic system.
- Elevated Lp(a) levels in MI patients without obstructive CAD suggest a mechanism beyond lipid metabolism.
- Further research is warranted to confirm the relationship between high Lp(a) concentrations and impaired fibrinolysis in cardiovascular disease.
Abstract:
It is generally accepted that Lp(a) is an independent risk factor of cardiovascular diseases. Since the apolipoprotein component of Lp(a) shows some homologies to plasminogen, it is, however, unclear as to whether the pathological effect is due to the role played by the lipoprotein in lipid metabolism or in the fibrinolytic system. We compared two groups of patients with myocardial infarction, with and without angiographically documented coronary artery disease. In the latter group, imbalances in the clotting system are very likely, while members of the former group may also display disturbances of lipid metabolism. The results show that the two groups display differences in lipid metabolism, whereas they have similar patterns of thrombogenicity indices and Lp(a) values. This study seems to support the hypothesis that Lp(a) does play a role in the fibrinolytic system, since even those myocardial infarctions without obstructive coronary artery disease have a high frequency of Lp(a) concentrations above 300 mg/l, i.e. similar to the situation found in the myocardial infarctions with angiographically documented coronary artery disease. Whether the high Lp(a) concentrations in the two groups are related to an impaired fibrinolysis will be the subject of further investigation.